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http://dx.doi.org/10.1016/j.stemcr.2016.10.004SUMMARYIn fragile X syndrome (FXS), CGG repeat expansion greater than 200 triplets is believed to trigger FMR1 gene silencing and disease eti-
ology. However, FXS siblings have been identifiedwithmore than 200CGGs, termed unmethylated fullmutation (UFM) carriers, without
gene silencing and disease symptoms. Here, we show that hypomethylation of the FMR1 promoter is maintained in induced pluripotent
stem cells (iPSCs) derived from two UFM individuals. However, a subset of iPSC clones with large CGG expansions carries silenced FMR1.
Furthermore, we demonstrate de novo silencing upon expansion of the CGG repeat size. FMR1 does not undergo silencing during
neuronal differentiation of UFM iPSCs, and expression of large unmethylated CGG repeats has phenotypic consequences resulting
in neurodegenerative features. Our data suggest that UFM individuals do not lack the cell-intrinsic ability to silence FMR1 and that
inter-individual variability in the CGG repeat size required for silencing exists in the FXS population.INTRODUCTION
FMR1 is an X-linked gene containing an array of CGG re-
peats located within the 50 UTR, which normally range
from 6 to 55 and may be unstable upon transmission to
the next generation (Biancalana et al., 2015).
Repeat numbers from 55 to 200, so-called premutation,
result in expression of mRNAwith expanded CGG repeats.
Individuals carrying the premutation are at risk of devel-
oping fragile X tremor ataxia syndrome (FXTAS, OMIM
#300623), a late-onset neurodegenerative disease (Hager-
man et al., 2001). One of the hallmarks of this disease is
ubiquitin-positive inclusion bodies, which have been de-
tected in postmortem brain samples (Greco et al., 2006).
A repeat expansion of more than 200 triplets (full muta-
tion) triggers gene silencing of FMR1, causing fragile X syn-
drome (FXS, OMIM#300624), themost common inherited
form of intellectual disability and autism (Verkerk et al.,
1991). Silencing is initiated during early embryonic devel-
opment and involves establishment of heterochromatin at
the FMR1 promoter, including DNA methylation (Sutcliffe
et al., 1992). FMR1 encodes the fragile Xmental retardation
protein (FMRP) and its absence impairs synaptic functions
(Willemsen et al., 2011).
Mosaicism in CGG repeat length is often observed in FXS
patients, who carry both premutation and full mutation
alleles and therefore differ in the proportion of cells with
silenced FMR1, which contributes to the clinical spectrumStem Cell Reports
This is an open access article under the Cof FXS phenotypes (Rousseau et al., 1994). Mosaicism in
the methylation pattern of the expanded CGG repeats
has also been described (Hagerman et al., 1994). So-called
unmethylated full mutation (UFM) individuals represent
an extreme case with all expanded alleles above 200 CGG
repeats being unmethylated. These individuals display no
signs of intellectual disability (Smeets et al., 1995; Tabolacci
et al., 2008;Wohrle et al., 1998) and only a handful of cases
have been identified worldwide. Molecular properties of
the FMR1 promoter have been studied in lymphoblastoid
cell lines and primary fibroblasts derived from UFM indi-
viduals (Pietrobono et al., 2005; Tabolacci et al., 2008).
Normal or slightly elevated FMR1 transcription, with
reduced FMRP level due to translational inefficiency, as
well as euchromatic configuration of the FMR1 promoter
have been demonstrated in these lines (Pietrobono et al.,
2005; Tabolacci et al., 2008). However, it is not clear
whether these cells have completely lost the ability to
methylate FMR1.
Human embryonic stem cells (ESCs) with more than
200 CGG repeats in the FMR1 locus as well as induced
pluripotent stem cells (iPSCs) from FXS patients have
been used to study the disease properties at a cellular level
(Avitzour et al., 2014; Colak et al., 2014; Eiges et al., 2007;
Sheridan et al., 2011; Telias et al., 2013; Urbach et al.,
2010). These human ESCs serve as a model for develop-
mental silencing of FMR1. In a fraction of ESC lines FMR1
is already repressed, whereas in some it is still active andj Vol. 7 j 1059–1071 j December 13, 2016 j ª 2016 The Author(s). 1059
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A C Figure 1. UFM Families
(A) Pedigrees of families with UFM sub-
jects. Oval, female; square, male; crossed,
deceased; white, normal; gray, premutation;
black, FXS; black onwhite pattern, UFM; blue,
buccal swap sample; red, blood sample.
(B) CGG repeat size in 50 UTR of FMR1
analyzed by PCR in UFMs and their families’
members. Additional analysis of the expan-
sion size by capillary electrophoresis in
UFM2 is provided in Figure S1.
(C) Percentage DNA methylation of 22 CpGs
of the FMR1 promoter analyzed by bisulfite
pyrosequencing in PBMC population. UFM
individuals display a minor proportion of
methylated alleles. Graph based on data in
Table S1.becomes silenced during in vitro neuronal differentiation
(Avitzour et al., 2014; Colak et al., 2014). In contrast, iPSCs
derived from FXS patients do not reactivate FMR1, suggest-
ing that the gene is locked in a silenced state that is resistant
to epigenetic reprogramming (Sheridan et al., 2011; Ur-
bach et al., 2010). Therefore, these cells are not used to
study the mechanism of FMR1 silencing, but for modeling
of neurological phenotypes of FXS (Sheridan et al., 2011;
Telias et al., 2013). In a recent study, iPSCs have been
also derived from one UFM individual (de Esch et al.,
2014). It has been reported that the cells gained silencing
of the FMR1 promoter upon reprogramming, hindering
the use of these cells for further analyses of the UFM
phenotype.
In this study we used somatic reprogramming to dissect
the relationship between repeat lengths and silencing
status in iPSCs from two unrelated UFM individuals. We
found that in the majority of iPSC clones FMR1 remained
unmethylated and active. However, in a small proportion
of clones which carried more than 400 CGGs FMR1 was
silenced, suggesting that theCGG repeat number necessary
to induce the silencing is400 in UFM individuals and not
200 as described for FXS. Moreover, we demonstrate that
upon selective pressure, unmethylated UFM clones gained
methylation accompanied by an expansion of the CGG
repeats above this higher threshold.1060 Stem Cell Reports j Vol. 7 j 1059–1071 j December 13, 2016Furthermore, the persistence of the UFM phenotype in
iPSC-derived neurons allowed us to investigate whether
cells carrying the expanded CGG repeat number and active
FMR1 develop a neurodegenerative phenotype. Indeed, we
found ubiquitin inclusion bodies in these cells, a pheno-
typic feature of FXTAS patients. We also observed that in
UFM as well as in premutation, iPSC-derived neurons
form FMRP inclusions that may contribute to the FXTAS
pathology.RESULTS
Genetic and Epigenetic Characterization of FMR1
Locus in UFM Individuals
Herewe describe one previously reported (Pietrobono et al.,
2005; Tabolacci et al., 2008) and one new UFM individual,
identified within two unrelated FXS families (Figure 1A).
Blood samples were obtained from both UFM individuals,
from their two healthy brothers N-B1 and N-B2, and the
FXS nephew of UFM1, F-N1 (Figure 1A). In addition, we
sampled buccal swabs from the additional living members
of the families (Figure 1A). For all, we determined CGG
repeat length by PCR amplification (Figure 1B). The full
expansion status (greater than 200 CGGs) was confirmed
for UFM and FXS individuals, as well as the premutation
status of their mothers. As expected, in premutation and
full mutation females we detected both expanded and
wild-type (WT) alleles. The CGG repeat expansion of
UFM individuals did not have a discrete length but dis-
played a continuous spectrum of sizes. This pattern is
observed for all reported UFM individuals to date and is
attributed to the somatic instability of unmethylated
repeats (Biancalana et al., 2015). For UFM1 repeat sizes
ranged from 200 to 500 CGGs and for UFM2 premutation
bands of 50 and 150 and a smear from 200 to 370 repeats
were detected, indicating amosaic status between a premu-
tation and full mutation (Figure 1B). Southern blot analysis
and capillary electrophoresis gave comparable results for
UFM1 (Tabolacci et al., 2008) and UFM2, respectively
(Figure S1).
We compared the DNA methylation status of the FMR1
promoter in the most closely related male individuals
with UFM, WT, and FXS phenotypes. We analyzed 22
CpGs within the FMR1 promoter using bisulfite pyrose-
quencing in peripheral blood mononuclear cells (PBMCs)
purified from blood. In cells from both UFMs the mean
DNA methylation was 4% and 6% for UFM1 and UFM2,
respectively, compared with 0.1% and 0.3% in two WT
(N-B1 and N-B2) individuals and 79% in an FXS patient
(F-N1) (Figure 1C and Table S1). The low level of
methylation in UFM PBMCs suggests the presence of fully
methylated alleles and, therefore, a low level of methyl-
ation mosaicism in these individuals.
CGG Repeat Sizes and FMR1 Expression States in UFM
iPSC Clones
PBMCs are composed of cells with heterogeneous CGG
repeat size and the FMR1 promoter methylation status. To
dissect the relationship between repeat size, methylation
status, and FMR1 expression, we derived iPSCs fromPBMCs
and performed analyses on multiple distinct clones.
Activated T cells were used for somatic reprogramming
by Sendai viruses harboring the SOX2, OCT4, c-MYC,
and KLF4 reprogramming factors (Takahashi et al., 2007).
A total of 11–12 clones were characterized from each
individual. All clones expressed markers of pluripotency
(Figure S2A) and were analyzed for the CGG repeat size,
the DNA methylation status of the promoter, and the
expression level of FMR1 (Figure 2 and Table S1).
The majority of clones obtained from both UFM individ-
uals had repeat sizes corresponding to the spectrum of sizes
observed in the PBMCs (Figure 2A). Three clones from
UFM1 displayed shorter CGG repeat sizes, with either
WT (UFM1-1) or premutation (UFM1-2 and UFM1-3) size.
This may represent either a contraction event or preexist-
ing lowly abundant alleles in the original PBMC samples.
The majority of UFM clones with repeat sizes above 200
CGGs retained the hypomethylated FMR1 promoter andexpressed FMR1 at levels comparable with WT (Figure 2).
Most of them showed discrete repeat sizes as expected
from the iPSC clonal derivation procedure. All clones
were analyzed between passages 5 and 10. A representative
UFM clone UFM1-5 was followed until passage 22 and
showed no changes in the hypomethylated status of the
FMR1 promoter and only slight CGG repeat instability (Fig-
ure S2B). We conclude that the UFM phenotype is stable
upon somatic reprogramming and is maintained in iPSCs.
Interestingly, 2 of 11 clones from UFM1 (UFM1-10
and UFM1-11) with the highest CGG repeat sizes (>450
CGGs) were hypermethylated and did not express FMR1.
In UFM2 we also identified 1 of 12 clones (UFM2-12) that
was silenced, hypermethylated, and carried more than
400 CGGs. However, a second silenced clone from UFM2
(UFM2-4) carried less than 200 CGGs. These silenced
clones may originate from the 5% methylated alleles
in PBMC samples or represent a de novo silencing event
during reprogramming.
We conclude that in the UFM individuals analyzed in
this study, the silencing threshold lies at 450 repeats in
UFM1 and 400 repeats in UFM2 (yellow lines in Figure 2A).
However, this threshold is less evident in UFM2 where an
outlier clone, UFM2-4, has been identified.
Silencing Threshold of CGG Repeat Length in FXS
iPSCs
The above results prompted us to investigate whether the
increased silencing threshold is a property exclusive to
these two UFM individuals. To this end, we analyzed iPSCs
from FXS patient F-N1, a nephew of UFM1 (Figure 3). In the
majority of F-N1 clones the FMR1 promoter was fullymeth-
ylated, an observation in line with the described resistance
of FMR1 silencing to the somatic reprogramming (Sheridan
et al., 2011; Urbach et al., 2010). However, we also identi-
fied two clones with active FMR1 (F-N1-1 and F-N1-2) and
repeat sizes above 200 CGG, but shorter than in the
silenced clones. The majority of the alleles in these clones
were hypomethylated (Figure 3 and Table S1).We conclude
that in this FXS patient the silencing threshold lies
around 400 CGG (yellow line in Figure 3A). Clones car-
rying the same size of 420 CGG were active in UFM1
(UFM1-7, UFM1-8, UFM1-9) and silenced in F-N1 (FN1-3).
We also derived iPSCs from an FXS individual not related
to the UFM families, from which iPSCs with the active
unmethylated full mutation allele of FMR1 have been pre-
viously described (Avitzour et al., 2014). Similarly to the
previous report, one of three analyzed clones was active
and fully unmethylated (Figure 3). The repeat size of this
clone ranged from 250 to 320 CGGs. A faint premutation
band of 80 CGGs was also detected. Nevertheless, 98% of
alleles were unmethylated. A smear indicating instability
of active expanded alleles was also observed. ConsistentStem Cell Reports j Vol. 7 j 1059–1071 j December 13, 2016 1061
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Figure 2. Increased Silencing Threshold in iPSC Clones Derived from UFM Subjects
(A) CGG repeat size in 50 UTR of FMR1 analyzed by PCR in iPSCs derived from PBMCs from UFM1 and UFM2. Background color of a clone name
indicates expression of FMR1 based on data in (B), expressing (blue), not expressing, or expressing below 5% of WT level (red). Circles
under the clone names indicate mean percentage of DNA methylation across 22 CpGs of the FMR1 promoter based on data in Table S1. Silent
and fully methylated clones are observed in both UFM subjects. Yellow lines indicate the proposed approximate thresholds of CGG repeat
numbers triggering FMR1 silencing in a given individual. The grey line corresponds to 200 CGG repeats. See also Figure S2.
(B) Expression of FMR1mRNA in iPSC clones from PBMCs from UFM1 and UFM2 analyzed by TaqMan assay. WT iPSC clone 86-14 derived from
a normal individual is included as a WT reference. Data are presented as a mean of three independent biological replicates. Error bars
represent SD.with a shift of the repeat threshold in this individual, the
two silenced clones FX97-2 and FX97-3 had repeat sizes
larger than 400 CGGs. We conclude that the threshold in
CGG repeat size resulting in silencing of FMR1 is subject
to inter-individual variation not only in UFM individuals
but also in a proportion of FXS patients.
De Novo Methylation of FMR1 in UFM iPSCs Is
Coupled with an Increase in the CGG Repeat Size
To assess whether UFM cells have intrinsic capacity to de
novo silence the FMR1 locus, we evaluated whether an1062 Stem Cell Reports j Vol. 7 j 1059–1071 j December 13, 2016active allele with a given repeat size can spontaneously
gain DNA methylation. Under extended cell culture up to
passage 22 we did not observe a spontaneous appearance
of methylated alleles for a representative clone UFM1-5
(Figure S2B). Therefore, we established a genetic system
to select for FMR1 silencing events. Our approach was
based on the fact that replicatingmammalian cells express-
ing the herpes simplex virus thymidine kinase (HSV-TK)
enzyme become sensitive to the prodrug ganciclovir
causing cell lethality, while non-expressing cells survive
and proliferate upon treatment. We deployed genome
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Figure 3. UFM-Like Clones and Altered
Silencing Threshold in iPSCs Derived from
FXS Patients
(A) CGG repeat size in 50 UTR of FMR1 analyzed
by PCR in iPSC clones derived from FXS patients.
Background color of a clone name indicates
expression of FMR1 based on data in (B), ex-
pressing (blue), not expressing or expressing
below 5% of WT level (red). Circles under
the clone names indicate mean percentage of
DNA methylation across 22 CpGs of the FMR1
promoter based on data in Table S1. Active,
hypomethylated clones with more than 200
CGGs are observed in both FXS patients.
Yellow line indicates the proposed approximate
threshold of CGG repeat numbers triggering
FMR1 silencing in these individuals. The grey
line corresponds to 200 CGG repeats.
(B) Expression of FMR1 mRNA in iPSC clones
derived from FXS patients analyzed by TaqMan
assay. WT iPSC clone 86-14 derived from a
normal individual is included as a WT reference.
Data are presented as a mean of three in-
dependent biological replicates. Error bars
represent SD.engineering to drive expression of a hygromycin-HSV-TK
fusion protein from the endogenous FMR1 promoter
(Figure 4A).
We inserted a selection cassette coding for a fusion of a
P2a peptide-hygromycin-HSV-thymidine kinase (Hyg-TK)
protein into exon 4 of the FMR1 gene in iPSC clone
UFM1-5 using the CRISPR/Cas9 system (Figures 4A and
S3A). This setup allowed for the direct hygromycin selec-
tion of correct insertions. After selection of clones we
confirmed a single integration event and analyzed their
CGG repeat length, FMR1methylation, and mRNA expres-
sion (Figures S3B–S3E). The clones were maintained in
hygromycin-supplemented medium to assure the absence
of cells with methylated FMR1 promoter. Two clones,
UFM1-5-6 and UFM1-5-7, with 250 and 320 CGG repeats,
respectively, were selected for further experiments. Unlike
the parental line UFM1-5 (Figure S3F), the knockin clones
were ganciclovir sensitive at concentrations of 5 and
10 mM after 3 days of prodrug treatment in the absence of
hygromycin (Figures 4B, 4C, and S3F). To allow the appear-
ance of spontaneous FMR1 silencing events, we culturedcells without hygromycin for 4 weeks (8 passages). Subse-
quent selection for silenced clones was performed using
10 mM ganciclovir for 3 days. The 4 weeks of hygromycin
withdrawal was necessary to observe reproducible appear-
ance of ganciclovir-resistant clones in UFM1-5-7, and
ganciclovir selection after shorter periods of hygromycin
withdrawal yielded no survivals. For the line UFM1-5-6
we did not observe any stable ganciclovir-resistant clones
(Figure 4D).
Most ganciclovir selected subclones did not survive
passaging, especially the ones which lost the iPSC
morphology. Importantly, we identified two clones with
iPSC morphology and stable ganciclovir resistance (Fig-
ure 4E). Both subclones UFM1-5-7-1 and UFM1-5-7-2
showed full methylation of the FMR1 promoter and CGG
repeat sizes of 800 CGGs, indicating that the expansion
of the CGG repeat led to the silencing of FMR1. We used
clone UFM1-5-7-1 in a follow-up experiment to test
the reversibility of the CGG expansion and methylation
by applying hygromycin selection. Interestingly, upon
withdrawal of ganciclovir we observed the appearance ofStem Cell Reports j Vol. 7 j 1059–1071 j December 13, 2016 1063
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Figure 4. Gain in CGG Repeat Number Is
Coupled with FMR1 Silencing in UFM iPSC
Clones
(A) Strategy to target a hygromycin resis-
tance-HSV thymidine kinase (HyTK) positive/
negative selection cassette into FMR1. In
this setup transgene expression is driven by
the endogenous FMR1 promoter. See also
Figure S3.
(B) Experimental design to select for iPSCs
that silence the FMR1 promoter driven HyTK.
Continuous hygromycin administration se-
lects for cells that express the transgene
making them sensitive to ganciclovir. Four
weeks without hygromycin allows appearance
of cells that spontaneously downregulate the
transgene. These cells can be selected for
by ganciclovir treatment. Subsequent DNA
analysis identifies clones with FMR1 promoter
methylation events.
(C and D) Crystal violet staining of surviving
cells after ganciclovir treatment of two
knockin iPSC clones (UFM1-5-6 and UFM1-
5-7) that were maintained: (C) under hy-
gromycin selection or (D) without hygrom-
ycin selection for 4 weeks.
(E) DNA methylation status and number
of CGG repeats of FMR1 from knockin iPSC
lines before and after hygromycin with-
drawal and subsequent ganciclovir selec-
tion. Lanes UFM1-5-6 and UFM1-5-7 are
the original clones before hygromycin
withdrawal. Subclones UFM1-5-7-1 and
UFM1-5-7-2 are derived from UFM1-5-7 af-
ter 4 weeks of hygromycin withdrawal and
subsequent ganciclovir selection. Circles
under each lane indicate mean percentage
of DNA methylation across 22 CpGs of the
FMR1 promoter for a given line based
on data in Table S1. Two ganciclovir-
resistant clones, UFM1-5-7-1 and UFM1-
5-7-2, gained 90% methylation and
have increased CGG repeats (800 CGG)
compared with the parental UFM1-5-7 (320
CGG). See also Figure S4.
(F) Crystal violet staining of surviving cells after hygromycin treatment of ganciclovir-resistant subclone UFM1-5-7-1. For cells maintained
with ganciclovir, no surviving colonies are observed. Upon ganciclovir withdrawal, spontaneous reactivation of FMR1 promoter is possible
and appearance of surviving colonies is observed.
(G) Analysis of two hygromycin-resistant colonies obtained from subclone UFM1-5-7-1 after withdrawal of ganciclovir as indicated in (F).
Parental clone UFM1-5-7 is analyzed in the first lane for direct comparison. CGG repeat sizes 320 and 150 indicate contraction events. Black
circles under each lane indicate mean percentage of DNA methylation across 22 CpGs of the FMR1 promoter based on data in Table S1. No
methylation is observed in the surviving colonies, indicating that contraction below the silencing threshold is associated with loss of DNA
methylation.‘‘revertant’’ hygromycin-resistant clones which coincided
with contraction of CGG repeats and loss of DNA methyl-
ation (Figures 4F and 4G).1064 Stem Cell Reports j Vol. 7 j 1059–1071 j December 13, 2016We conclude that the silencing of FMR1 in UFM iPSCs
directly depends on the size of the CGG repeat. Further-
more, UFM cells have not lost the capacity to silence
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Figure 5. UFM iPSC Derived Neurons Do
Not Undergo Developmental Silencing
of FMR1
(A) Expression of FMR1mRNA during 90 days
of neuronal differentiation of iPSC lines with
variable repeat length and methylation.
Timing of FMR1 silencing in FXS human ESCs
as reported by Colak et al. (2014) is indi-
cated and no significant drop of FMR1 mRNA
expression is observed before or after this
time in any line. Black circles next to each
line indicate mean percentage of DNA
methylation across 22 CpGs of the FMR1
promoter at day 90 of differentiation. Data
points represent mean of three independent
differentiations ± SEM. See also Figure S5.
(B) Antibody staining of FMRP, the protein
product of FMR1, in iPSC-derived neurons at
day 60 of neuronal differentiation. FMRP,
red; DAPI, blue. Except for the UFM1-11 clone
with fully methylated and silent FMR1, FMRP
was detected in all clones. Scale bar, 20 mm.FMR1. Consistently, we did not find any mutation com-
mon to the two UFMs that would obviously impair
the silencing machinery (Figure S4A; Tables S2 and S3).
Neither did we identify a common mutation in the
proximal regulatory sequences of FMR1 (Figures S4B–S4D).
FMR1 Silencing Status Is Not Affected by
Differentiation of UFM iPSC Clones
The conversion of an active UFM allele to a silenced one
required an increase of the CGG repeat length. However,
switching from an active to a silenced state, without
changes in the repeat size, underlies the process of develop-
mental silencing of FMR1 in FXS embryos and has been
modeled by neuronal differentiation of FXS human ESCs
(Colak et al., 2014; Eiges et al., 2007; Sutcliffe et al., 1992;
Telias et al., 2013). Therefore, we evaluated the stability
of FMR1 expression during neuronal differentiation of
UFM iPSCs.
The exact time window of FMR1 silencing during in vitro
differentiation of FXS human ESCs to cortical neurons has
been reported at day 45 (Colak et al., 2014). We applied
the same differentiation protocol to iPSCs from two UFM
individuals with variable CGG repeat sizes and FMR1
silencing status (Figure 5).We used four iPSC lines with un-
methylated expanded repeats, namely UFM1-5 (320 CGG),
UFM1-9 (420 CGG), UFM2-5 (200 CGG), and UFM2-9 (260
CGG), as well as iPSC clone UFM1-11 with methylated
expanded repeats of 480 CGG. Two WT lines, either with
UFM1 background (UFM1-1) or from an unrelated healthy
donor 86-14, were used as controls. All lineswere efficiently
differentiated into class III b-tubulin/MAP2-positive neu-rons (Figure S5). We analyzed the expression level of
FMR1mRNA at four time points, up to 90 days of neuronal
differentiation (Figure 5A). At day 60 we additionally
confirmed the presence of FMRP by immunofluorescence
(Figure 5B). For all the lines with active FMR1 we observed
a gradual increase in the expression during differentiation
(Figure 5A), consistent with the described dynamics of
FMR1 expression during neuronal differentiation of WT
human ESC lines (Telias et al., 2013).We also did not detect
the appearance of any methylated FMR1 alleles at day 90
(Figure 5A). No major changes in the size of the CGG re-
peats were found at this time point (data not shown).
Also the methylation status of clone UFM1-9, which had
8% of its alleles methylated in the iPSC state, did not
change during differentiation into neurons (7%–10%
in three independent differentiations). In addition, line
UFM1-11, with the longest CGG repeat size (480), retained
full methylation of the FMR1 promoter.
We conclude that the silencing status of FMR1 is a stable
feature of a given repeat size in the UFM background.
Furthermore, this result shows that UFM cells are not sub-
jected to developmental silencing induced by neuronal
differentiation.
iPSC-Derived Neurons from UFM Subjects Show
Phenotypic Properties of FXTAS
Ubiquitin-positive inclusion bodies (IBs) are found in
postmortem brain samples of FXTAS patients (Greco
et al., 2006) and in mouse models of FXTAS (Wenzel
et al., 2010) expressing the FMR1with repeat sizes between
50 and 200 CGG. Therefore, to analyze the phenotypicStem Cell Reports j Vol. 7 j 1059–1071 j December 13, 2016 1065
Figure 6. Neurodegenerative Features of
UFM iPSC-Derived Neurons
(A) Representative images of staining for
ubiquitin and FMRP inside GFP-labeled,
isogenic, iPSC-derived neurons with spec-
trum of CGG repeat sizes corresponding toWT
(UFM1-1), classical premutation (UFM1-3),
UFM (UFM1-5 and UFM1-9), and FXS (UFM1-
11). The iPSC-derived neurons were cultured
within murine brain slices for 6 weeks.
Ubiquitin (Ubi), red; FMRP, magenta; GFP,
green; DAPI, blue. Multiple ubiquitin-posi-
tive inclusion bodies (IBs) are detected in
UFM lines UFM1-5 and UFM1-9. Punctuated
staining of FMRP is observed in UFM1-3,
UFM1-5, and UFM1-9. Scale bars, 2 mm.
(B) Number of ubiquitin IBs per cell body of
GFP-labeled human neuron. IBs R0.5 mm
were counted. Black and gray bars represent
FMRP-positive and -negative cells, respec-
tively. Increased number of IBs is observed
in both UFM clones but only for cells ex-
pressing FMRP. n = 15–50 cells per line
coming from three independent rounds of
brain slice injections (three mice). Data are
presented as mean ± SEM; ***p < 0.0001,
unpaired Student’s t test.
(C) Number of FMRP foci per cell body of GFP-
labeled human neuron. FMRP fociR0.5 mm
were counted. For UFM1-9 only cells ex-
pressing FMRP are quantified. n = 15–50
cells per line coming from three indepen-
dent rounds of brain slice injections (three
mice). Data are presented as mean ± SEM;
***p < 0.0001, unpaired Student’s t test.consequences of the expression of FMR1 with more than
200 repeats, we analyzed the numbers of ubiquitin-positive
IBs in UFM iPSC-derived neurons (Figure 6). To enhance
thematuration of neuronal precursors we used a co-culture
system, whereby iPSC-derived neuronal progenitors are
transiently transfected with a GFP expression vector and
injected into organotypic mouse brain slices (OTBS) con-
taining cortex, striatum, and hippocampus (Pecho-Vriesel-
ing et al., 2014). After 6 weeks of co-culture we compared
the number of ubiquitin IBs in isogenic iPSC-derived neu-
rons only differing in the repeat size. UFM1-5 (320 CGG)
and UFM1-9 (420 CGG), which expressed FMR1, were eval-
uated for the FXTAS phenotypewhereasUFM1-1 (20CGG),
UFM1-3 (150 CGG), and UFM1-11 (480 CGG) with
silenced FMR1 served as WT, premutation, and FXS con-
trols, respectively (Figure 2). We found multiple ubiquitin
inclusions throughout the cell bodies of GFP-positive
human neurons (Figures 6A and 6B). We quantified the
number of inclusions in both cytoplasm and nucleus and
found significantly higher numbers in the UFM clone1066 Stem Cell Reports j Vol. 7 j 1059–1071 j December 13, 2016(UFM1-5) compared with WT (UFM1-1) (Figures 6A
and 6B). This effect was not observed for premutation
(UFM1-3) neurons, indicating that expression of mRNA
with 150 CGG repeats is not sufficient to trigger the effect.
All the quantified cells in clones UFM1-1, UFM1-3, and
UFM1-5 expressed FMR1 as judged from FMRP staining.
For UFM clone UFM1-9 with 8% methylated alleles we
observed that only a proportion of neurons expressed
FMRP and found a significantly higher number of inclu-
sions only in these cells. The proportion of neurons that
did not express FMRP did not show this effect, similar to
neurons from FXS clone UFM1-11 with fully methylated
FMR1 (Figures 6A and 6B). Thus, expression of FMR1
with expanded repeat is required for the accumulation of
ubiquitin IBs.
In addition, we observed a dotted, aggregate-like pattern
of FMRP staining in neurons derived from premutation
(UFM1-3) and both UFM clones (UFM1-5 and UFM1-9)
compared with an even distribution of FMRP in WT
(UFM1-1) neurons (Figures 6A and 6C). We quantified the
number of these FMRP aggregate-like structures in
neuronal cell bodies and found a significant increase in
premutation and UFM neurons compared with WT (Fig-
ure 6C). As expected, no FMRP staining was observed in
FXS (UFM1-11) neurons.
These data together suggest that UFM neurons may
develop FXTAS neurodegenerative pathology. Moreover,
some pathological phenotypes were only present or more
pronounced in UFM when being compared with premuta-
tion neurons.DISCUSSION
Genotype-phenotype correlation is greatly affected by
inter-individual genetic differences and external factors.
This variability is particularly relevant for the penetrance
of genetic variants and may explain the spectrum of clin-
ical phenotypes. In extreme cases, individuals who carry
a pathological mutation may lack disease features. Dissect-
ing the correlation between genotype and phenotype in
these individuals may provide novel insights into the
disease.
FXS is caused by a CGG trinucleotide repeat expansion
in the 50 UTR of FMR1 that leads to its developmental
silencing. There is a broadly accepted consensus that 200
CGGs represent the threshold above which the FMR1 pro-
moter becomes methylated and its transcription is turned
off (Biancalana et al., 2015; Willemsen et al., 2011). An
exception to this rule has been identified in rare UFM indi-
viduals who do not silence FMR1 despite the expansion
above this threshold (Smeets et al., 1995; Tabolacci et al.,
2008; Wohrle et al., 1998). Whether these individuals
have lost the capacity to silence FMR1 locus has so far
remained elusive.
In this study, we demonstrate that in two unrelated UFM
cases FMR1 silencing is not completely impaired. However,
we found that the CGG repeat number necessary to trigger
silencing is around 400 CGG rather than 200 CGG
described for FXS patients. Analysis of iPSC clones with
a spectrum of discrete repeat sizes allowed us to dissect
the relation of CGG repeats with the silencing status of
FMR1, previously only evaluated in primary cells and tis-
sues with complex mosaic patterns of CGG repeat lengths.
We show that in the majority of iPSC clones derived from
the two UFM subjects, the FMR1 promoter was unmethy-
lated and active (Figure 2). In contrast, clones from FXS
subject F-N1 in majority were silenced (Figure 3). However,
also in a fraction of UFM clones with more than 400 CGG
repeats FMR1wasmethylated and not expressed. An excep-
tion to this was the methylated clone UFM1-4 with 180
CGG repeats. It is not fully exceptional for a high premuta-
tion to be methylated, although very infrequent (Rousseauet al., 1994; G.N., unpublished data). Moreover, we de-
tected5%methylated alleles in blood of bothUFMs, indi-
cating that silencing of FMR1 in UFM background is not
an artifact of iPSCs but occurs in vivo as well (Figure 1C).
To test whether UFM iPSCs are capable of de novo
methylation and silencing of FMR1, we applied a selection
pressure paradigm to unmethylated expanded alleles (Fig-
ure 4). Indeed, we found very rare events of methylation
gain that were associated with amajor increase in the num-
ber of CGG repeats. This demonstrates that UFM iPSCs are
capable of gaining DNAmethylation at the FMR1 promoter
when theCGG size is higher than their silencing threshold.
By using a reporter knocked into the FMR1 gene we moni-
tored the silencing events in the endogenous locus that al-
lowed us to evaluate if both cis and trans components of
silencing machinery are in place in UFM cells. This is espe-
cially relevant, as the CGG-mediated silencing of FMR1 has
not been recapitulated in the transient transfection or
randomly integrated reporter assays (Solvsten and Nielsen,
2011). The result of our experiment suggests that UFM
individuals possess all the necessary components for the
silencing of FMR1. Consistent with this notion, we have
not identified any obvious genetic mutation common to
both UFM individuals by analyzing the exome sequence
of components of the epigenetic machinery and the regu-
latory sequences of the FMR1 locus, including the sequence
of the CGG repeat implicated in silencing initiation (Colak
et al., 2014) (Figure S4).
Little is known about why the silencing threshold lies at
200 CGG repeats in FXS. In human ESCs carrying unme-
thylated CGG expansions a formation of a DNA:RNA
hybrid over the CGG repeat is required for silencing initia-
tion (Colak et al., 2014). Recently the direct dependence of
FMR1 silencingmaintenance on the expanded CGG repeat
has been demonstrated by removal of the repeat with
CRISPR/Cas9 in FXS iPSCs, which resulted in demethyla-
tion and reactivation of the FMR1 (Park et al., 2015).
Here, by using a selection strategy we demonstrate that
by increasing the length of the repeat an active FMR1 allele
becomes silenced and furthermore that it can be reverted
to an active state upon a contraction event (Figure 4).
Therefore, the dependence of the FMR1 activity on the
repeat length is bidirectional. Our selection system pro-
vides a tool to further study the dynamics of FMR1
silencing.
The FMR1 gene with more than 200 CGG repeats is
silenced during early embryonic development (Sutcliffe
et al., 1992). This process has been modeled in human
ESCs derived from embryos carrying the FMR1 full mu-
tation. In these cells FMR1 is silenced during in vitro
neuronal differentiation (Colak et al., 2014; Eiges et al.,
2007; Telias et al., 2013). Unfortunately, it is not possible
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recent study suggests that there is genetic and epigenetic
equivalence of human ESCs and iPSCs with matched
genetic background (Choi et al., 2015). Therefore, we inves-
tigated whether UFM iPSC clones with a spectrum of un-
methylated repeat lengths would silence FMR1 in this
developmental model (Figure 5). We neither observed a
drop in the expression nor an appearance of methylated
alleles at all analyzed stages of neuronal differentiation.
Additionally, the silenced methylated status of cells with
more than 450 CGG repeats did not change. These data
suggest that the activity status of an allele with a given
repeat size is maintained in iPSC-derived neurons. Further-
more, the expanded unmethylated alleles are resistant to
silencing during differentiation. If the lack of methylation
in UFM was a result of a maternal effect or stochastic
events, FMR1would have been silenced during in vitro dif-
ferentiation as observed in human ESCs carrying the FMR1
full mutation (Colak et al., 2014; Eiges et al., 2007; Telias
et al., 2013). However, our data suggest that the UFM cells
possess intrinsic properties that affect their silencing
threshold causing the lack of FMR1 methylation during
neuronal differentiation.
Recently, iPSCs were derived from fibroblasts obtained
from another unrelated UFM subject (de Esch et al.,
2014). The lymphoblastoid cell line from this subject has
been previously characterized and showed the same epige-
netic profile of the FMR1 promoter-like lymphoblastoid
cells from UFM1 (Pietrobono et al., 2005; Tabolacci et al.,
2008). However, the authors reported that upon iPSC deri-
vation the FMR1 promoter gained methylation and the
FMR1 expression was shut off in all derived clones (de
Esch et al., 2014). Inter-individual heterogeneity of the
UFM group may be the cause of different results of UFM re-
programming in our study. Alternatively, different sources
of the material being fibroblasts and PBMCs in de Esch
et al. (2014) in their two respective studies may have led
to this discrepancy. However, we reproduced the results
of Avitzour et al. (2014) obtaining a UFM-like clone from
an independent FXS fibroblast line (GM09497, Figure 3),
which suggest that different cell type origins alone would
not result in clones with different silencing status. Further-
more, the results from de Esch et al. (2014) are in agree-
ment with our observation that UFM subjects retain the
ability to silence FMR1. In addition, the published data
may well be interpreted in favor of an altered silencing
threshold. The fibroblasts used by de Esch et al. (2014)
for reprogramming carried the repeat sizes of 200–230
CGGs. The CGG size disclosed for two silent iPSC clones
in de Esch et al. (2014) were 330 and 380 repeats. The
difference between the original repeat size of the fibro-
blasts and the one reported in the iPSC clones with silent
FMR1 is in line with our hypothesis of a shifted silencing
threshold in UFM individuals.1068 Stem Cell Reports j Vol. 7 j 1059–1071 j December 13, 2016Our observation of the variability in the silencing
threshold is not limited to the UFM group, as we also de-
tected this phenomenon in FXS patients. From a UFM-
related FXS subject F-N1 and from an unrelated patient,
FX97 (derived from GM09497 fibroblasts), we derived
iPSC clones (Figure 3). All clones from both individuals car-
ried FMR1 alleles withmore than 200 CGG repeats, most of
them being silenced as previously described for FXS iPSCs
(Sheridan et al., 2011; Urbach et al., 2010). However,
some of the clones were active, hypomethylated, and had
lower CGG repeat sizes than the silenced ones, consistent
with a shift in the FMR1 silencing threshold in these cells.
Interestingly, in a recent report iPSCswere derived from the
same fibroblasts GM09497 (Avitzour et al., 2014). Among
four clones one was carrying an active FMR1 allele with a
fully expanded repeat, while the remaining three were
silenced. The exact repeat size of the clones is not reported.
Nevertheless, these data show the reproducibility of our
results and indicate that the shift in the repeat threshold
is an intrinsic property of the cells and not a random phe-
nomenon. Our data support the hypothesis that the num-
ber of CGG repeats that triggers the epigenetic silencing of
the FMR1 promoter may vary between individuals.
In our model, the persistence of the increased silencing
threshold in UFM iPSC-derived neurons prevents the
development of the FXS phenotype. However, the ex-
pressed expanded CGG repeat is predicted to give rise to
an additional phenotype in these neurons. Individuals
that carry active FMR1 alleles with 50–200 CGG repeats
(permutation) are at risk of developing the late-onset
neurodegenerative disease FXTAS, and there have been re-
ports of FXTAS diagnosis in UFM individuals (Basuta et al.,
2015; Loesch et al., 2012). Key hallmarks of this disease are
relatively large, single per cell, intra-nuclear ubiquitin-pos-
itive IBs found in postmortem brain samples from FXTAS
patients as well as in mouse models (Greco et al., 2006;
Wenzel et al., 2010). At the cellular level FXTAS phenotype
has been explored in iPSCs from a premutation individual
carrying an expansion of 94 CGG repeats (Liu et al., 2012).
However, the authors did not report on the presence of
ubiquitin IBs. In the FXTAS brain samples a correlation
of the CGG repeat number and the percentage of neurons
with IBs has been observed (Greco et al., 2006). Therefore,
iPSCs that express FMR1 mRNA with more than 200 CGG
repeats may potentially show enhanced or accelerated
FXTAS phenotypes. Indeed, we find that neurons car-
rying more than 200 CGG repeats showed significantly
increased numbers of ubiquitin-positive IBs compared
with WT neurons (Figure 6B). This effect was not present
in cells with silenced FMR1 as judged by FMRP staining,
indicating that not the expansion per se but the expres-
sion of the expended repeat is necessary to trigger the
effect.
We did not observe an increased number of ubiquitin IBs
in neurons derived from an isogenic iPSC line with a clas-
sical premutation length. It is likely that the expression
of mRNAwith longer CGG repeat lengths in UFM neurons
results in accelerated pathological development compared
with premutation neurons. Furthermore, in contrast to a
single large intra-nuclear IB observed in FXTAS mouse
models or in postmortem brain samples of FXTAS patients,
we found multiple IBs in both cytoplasm and nucleus. The
iPSC-derived neurons represent an early developmental
stage in comparison with an aging brain. Developmental
progression of the number and size of the inclusions is
reported in FXTAS mice (Wenzel et al., 2010). Therefore,
the pattern of ubiquitin inclusions observed here may
reflect an early stage of the IB formation at the onset of
the disease. Additionally we detected that both premuta-
tion and UFM neurons show increased numbers of FMRP
aggregate-like structures (Figure 6C). FMRP has been re-
ported to have a tendency to aggregate and spontaneously
misfold toward b-rich structures in vitro (Sjekloca et al.,
2011). Therefore, aggregation of FMRP may be contrib-
uting to the FXTAS pathology. Overall, our data provide
evidence for an increased accumulation of ubiquitin and
FMRP inclusions in UFM iPSC-derived neurons, which
may be signs of an accelerated FXTAS phenotype in the
UFM lines compared with the classical premutation.
In summary, our analyses reveal that UFM individuals
have not lost the ability to silence FMR1, but the size of
the CGG expansion triggering the silencing is higher
than the one described in FXS patients (200 CGG). Further-
more, inter-individual variability in the CGG size requited
for silencing is present not only in UFMbut also in two FXS
patients analyzed in this study. We propose a model in
which the threshold size together with the proportion of
the FMR1 alleles below this threshold delineates UFM and
FXS phenotypes. UFM do not silence FMR1 and are spare
of FXS pathology; nevertheless, our data suggest that the
expression of FMR1 gene with large CGG expansion may
increase their risk of developing FXTAS.EXPERIMENTAL PROCEDURES
Ethics and Sample Collection
The sample collection and all of the Experimental Procedures
were approved by the Ethics committees of theCatholicUniversity
School of Medicine in Rome and the Ethikkommission Nordwest-
und Zentralschweiz. Proper informed consent was obtained from
all donors. Blood samples were collected from UFM individuals,
their healthy brothers, and FXS nephew of UFM1. Buccal swab
samples were obtained from additional family members. Primary
skin fibroblasts GM09497 were obtained from Coriell Institute
for Medical Research. Experiments involving mice were carried
out in accordance with authorization guidelines of the SwissFederal and Cantonal veterinary offices for care and use of labora-
tory animals and were approved by the Swiss Cantonal veterinary
office and performed according to Novartis animal license number
2063.
FMR1 DNA Methylation, CGG Repeat Length, and
Expression
CGG repeat number in the 50 UTR of FMR1 was analyzed by PCR
amplification using an AmplideX FMR1 PCR kit (Asuragen) and
agarose gel electrophoresis if not stated differently. DNA methyl-
ation of 22 CpGs of the FMR1 promoter was analyzed using
bisulfite pyrosequencing by EpigenDx. Expression of FMR1 was
quantified using TaqMan assay Hs00924547_m1 (Thermo Fisher).
See Supplemental Experimental Procedures for the details.
iPSC Derivation and Neuronal Differentiation
iPSCs were derived from activated T cells isolated from PBMCs us-
ing a CytoTune-iPS Reprogramming Kit (Invitrogen). iPSCs were
cultured on Matrigel (Corning) in mTeSR medium (Stem Cell
Technologies) or Nutristem (Biological Industries). iPSCs were
differentiated to neurons using the dual SMAD inhibition protocol
(Chambers et al., 2009). Neuronal precursor cells derived from
iPSCs were differentiated either on Matrigel or on OTBS using a
previously described method (Pecho-Vrieseling et al., 2014). For
detailed iPSC derivation and differentiation protocols, see Supple-
mental Experimental Procedures. The iPSC lines generated in this
study are available upon request for research to study FXS and
related diseases if all legal and ethical standards are met.
Immunostaining and Image Analysis
Immunostaining was performed using standard procedures ex-
plained in detail in Supplemental Experimental Procedures, using
the following antibodies: rabbit anti-class III b-tubulin (PRB-435P,
BioLegend), chicken anti-MAP2 (ab5392, Abcam), mouse anti-
FMRP (Sc-101048, Santa Cruz Biotechnology), and rabbit anti-
ubiquitin clone 10H4L21 (701339, Thermo Fisher). Images were
acquired with a Zeiss confocal microscope. Ubiquitin and FMRP
spots lying within the GFP-positive human neurons were counted
manually using visualization with Imaris software as described
in Supplemental Experimental Procedures.
Thymidine Kinase Knockin and Positive-Negative
Selection
A P2a peptide-hygromycin-HSV thymidine kinase-stop codon-
SV40 poly(A)(Hyg-TK) cassette was inserted into exon 4 of FMR1
using CRISPR-mediated homologous recombination. For the de-
tails of construct generation, validation, and selection procedure,
see Supplemental Experimental Procedures. Knockin lines were
maintained in Nutristem medium (Biological Industries) supple-
mented with 25 mg/mL hygromycin. Positive-negative selection
was performed with 10 mM ganciclovir without hygromycin.
Exome Sequencing, FMR1 Promoter, and CGG
Sequencing
Details of exome sequencing, Sanger sequencing of FMR1 pro-
moter, and single-molecule real-time sequencing (SMRT) of theStem Cell Reports j Vol. 7 j 1059–1071 j December 13, 2016 1069
CGG repeat tract are described in Supplemental Experimental
Procedures.Statistical Analysis
Statistical analysis in Figure 6 was performed with Prism (Graph-
pad) software. The unpaired Student’s t test was used to determine
significant differences between groups. Random samples from
each mouse were taken. No mice and data points were excluded
from the analysis. OTBSs that showed a severe degeneration
of both hemispheres (measured as holes in the cultures) were
excluded from the analysis.ACCESSION NUMBERS
Exome sequencing data have been deposited at the European
Genome-Phenome Archive (EGA, https://ega-archive.org), under
accession number EGAS00001001737. The data are accessible to
the FXS research community via the controlled access procedure
of the EGA.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, five figures, and three tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2016.10.004.
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